Connecticut Attorney General Announces Settlement with Apotex for Inflating Generic Drug Prices

Recent Settlement with Apotex Corp: What Consumers Need to Know

In a significant development for consumers, the Connecticut Office of the Attorney General has announced a proposed settlement with Apotex Corp., a manufacturer of generic prescription drugs. This settlement resolves ongoing litigation related to accusations of illicit practices that inflated drug prices and curtailed competition among manufacturers.

Background of the Lawsuit

The lawsuits involved, labelled the States' Claims and collective claims from End-Payer Plaintiffs (EPP), allege that Apotex and other defendants colluded to artificially raise the prices of numerous generic prescription medications sold in the United States between January 1, 2009, and December 31, 2019. As a consequence of these actions, many consumers may have overpaid for medications that should have been more affordable.

Who is Affected?

Eligible consumers include those who purchased specific generic drugs manufactured by Apotex within the designated timeframe. Consumers who believe they fit this description are encouraged to seek out further information to understand whether they qualify for potential compensation. More comprehensive details, including a complete list of the affected medications and eligibility criteria, can be found at AGGenericDrugs.com or by calling 1-866-290-0182.

Financial Aspects of the Settlement

Under the terms of the settlement with Apotex, the company is set to pay a total of $39.1 million. Out of this amount, approximately $17.6 million is earmarked for consumer restitution, while around $9.7 million is allocated to certain governmental entities. Additionally, $11.7 million will cover notification expenses, administrative costs, and expenses related to the ongoing litigation against remaining defendants who have not yet reached a settlement.

Claims Process

Although the settlement has been reached, distribution of the funds will not occur until the court provides the necessary approval. A claims process is set to open at a later date, requiring affected consumers to submit a claim form to receive compensation. Interested parties should keep an eye on updates and instructions regarding the claims process, which will be made available on the AGGenericDrugs.com website.

Consumers are advised that if they do not take any action, they will be bound by the agreement and the court's decisions. Those wishing to preserve their right to take separate legal action against non-settling defendants must opt out of the settlement by July 24, 2025. They may also voice any objections or concerns regarding the settlement while still remaining part of the litigation.

Upcoming Court Hearings

There will be a hearing on August 12, 2025, in the U.S. District Court for the District of Connecticut, and another on October 3, 2025, in the U.S. District Court for the Eastern District of Pennsylvania. These hearings will assess whether the proposed agreement should be approved.

Conclusion

This settlement marks an important victory for consumers impacted by the alleged price-fixing activities in the generic drug market. Those who may have been affected should actively seek information and prepare for the forthcoming claims process to ensure they receive their rightful compensation. Remember to visit AGGenericDrugs.com for the latest updates and information on this major settlement.